Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India’s Lupin Says Ready To Present Mandideep Plan To U.S. FDA; Push On Novel Drug Delivery, Biosimilars And Indian Market To Propel Revenue Growth

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Indian drug maker Lupin hopes to clear up issues with U.S. regulators on its Mandideep-based manufacturing unit, which has been issued warning letters by the U.S. FDA. The FDA had charged the facility deviated from current good manufacturing practices in the production of oral and injectable cephalosporins in November 2008

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts